Chinese Drug Maker Clarifies Development Strategy For Bringing Cancer Drug To The U.S. Market

Given these plans, Chi-Med is open to U.S. partnerships for development of cancer therapies that incorporate fruquintinib.

Read the full post on Forbes - Healthcare